1. Market Research
  2. > Pharmaceutical Market Trends
  3. > Research and Development Forecast of China Pharmaceutical Chain Market, 2013-2017

Huidian Research issues Research and Development Forecast of China Pharmaceutical Chain Market, 2013-2017. Firstly the report makes the overview of China pharmaceutical circulation industry’s development, makes the introduction and analysis of the industry’s management system and related policies and further points out the future investment opportunities of China’s pharmaceutical circulation field. Secondly it makes the deep analyses of the development status quo, advantages, existing problems and access barriers etc. of the pharmaceutical chain industry as well as the special chapter analysis of China’s top 100 pharmaceutical retail enterprises. Lastly it makes the future development forecast of China’s pharmaceutical chain, which can provide the decisive reference for the investment in the industry.

Influencing by the rapid development of China’s pharmaceutical industry and the increasing aging population, the pharmaceutical retail market develops rapidly, chain enterprises continuing the expansion and the number of the pharmacies increasing continuously. By the end of 2012, the sales amount of China’s top 100 pharmaceutical retail enterprises reached CNY 87.877 billion, up 17.51% compared to last year, with the share of 39.06% in China’s pharmaceutical retail market. The total number of branches of the top 100 enterprises’ direct sale-stores was 50,418 in 2012, up 4.96% year on year.

In the increasing market competition, the pharmaceutical retail market maintains the rapid development situation. With the promotion of the construction of Two Networks (pharmaceutical supply network and pharmaceutical monitoring network) and the reform of new cooperative medical care system in the rural areas, the rural pharmaceutical market gets the development, becoming the key areas of the future expansion of chain drugstores. With gradual perfect and comprehensive implementation of the new medical care system reform, China’s pharmaceutical retail market ushers the wonderful development opportunity, the pharmaceutical chain industry entering the period of the strategic opportunity with brand development prospect. During the 12th-Five-Year period, the proportion of chain drugstores will account for two thirds of the total drugstores and will be equipped comprehensively with licensed pharmacists.


Please note: The report is Chinese version. It will provide the English version in two business days.

Table Of Contents

Research and Development Forecast of China Pharmaceutical Chain Market, 2013-2017
Table of Contents

1. Development of China's Pharmaceutical Circulation Industry
1.1 Model and Main Business Forms of Pharmaceutical Chain
1.1.1 Business Model
1.1.2 Main Business Forms of Pharmaceutical Retails
1.2 Brief Introduction to the Development of China's Pharmaceutical Circulation
1.3 Management System and Related Policies of the Industry
1.3.1 Competent Authorities
1.3.2 Main Laws and Regulations
1.4 Future Investment Opportunities of the Pharmaceutical Circulation Industry
1.4.1 Enterprises with Innovative Distribution Model
1.4.2 Retail Chain Pharmacies
1.4.3 Providers of the Pharmaceutical Supply Chain Added-Value Service
1.4.4 Standardized Third-Party Drug-Promotion Enterprises

2. Overview of China's Pharmaceutical Chain Industry
2.1 Definition and Characteristics of Chain Business
2.1.1 Definition
2.1.2 Characteristics
2.1.3 Forms
2.2 Development Overview of China's Chain Pharmacies
2.3 Reasons for the Rapid Development of China's Chain Pharmacies
2.3.1 Powerful Support of the Government
2.3.2 Market Demands
2.3.3 Competitive Needs
2.3.4 Own Development Needs
2.4 Advantages of China's Chain Business Pharmacies
2.4.1 Brand
2.4.2 High Quality Staff
2.4.3 Scale
2.4.4 Business and Management
2.4.5 Low Price
2.4.6 Channel Network
2.4.7 Professional Service
2.5 Problems Existing in China's Chain Pharmacies
2.5.1 Small Scale and Large Quantity
2.5.2 Shortage of Talents
2.5.3 Imperfect Information System
2.5.4 Lacking the Perfect Distribution Center
2.6 Industry Barriers to Entry
2.6.1 Business Qualifications
2.6.2 Channel Barrier
2.6.3 Scale Barrier
2.6.4 Capital Demand
2.6.5 Brand Barrier
2.7 Special Analysis of China Pharmacy Union

3. Special Analysis of China's Top 100 Pharmaceutical Retail Enterprises

4. Key Enterprises of China's Pharmaceutical Chain
4.1 Sinopharm Holding Guoda Drugstores Co., Ltd.
4.1.1 Company Profile
4.1.2 Operation Conditions
4.1.3 Chain Store Network
4.2 Chongqing Tongjunge Pharmacy Chain Store Co., Ltd.
4.2.1 Company Profile
4.2.2 Operation Conditions
4.2.3 Chain Store Network
4.3 Guangdong Dashenlin Chain Drugstore Co., Ltd.
4.3.1 Company Profile
4.3.2 Operation Conditions
4.3.3 Chain Store Network
4.3.4 Future Development Strategy
4.4 China Nepstar Chain Drugstore Co., Ltd.
4.4.1 Company Profile
4.4.2 Operation Conditions
4.4.3 Chain Store Network
4.5 Chongqing Peace Pharmacy Chain Co., Ltd.
4.5.1 Company Profile
4.5.2 Operation Conditions
4.5.3 Chain Store Network
4.5.4 Future Development Strategy
4.6 Yunnan Hongxiang Yixintang Pharmaceutical Co., Ltd.
4.6.1 Company Profile
4.6.2 Operation Conditions
4.6.3 Chain Store Network
4.7 Hubei Tongjitang Pharmacy Co., Ltd.
4.7.1 Company Profile
4.7.2 Operation Conditions
4.7.3 Chain Store Network
4.7.4 Future Development Strategy
4.8 Liaoning CDFY Pharmacy Chain Co., Ltd.
4.8.1 Company Profile
4.8.2 Operation Conditions
4.8.3 Chain Store Network

5. Future Development of China's Pharmaceutical Chain
5.1 Exploring Rural Market and Large Healthy Concept Becoming the Trend
5.2 Development of Online Pharmacies
5.2.1 Management of China's Online Pharmacies
5.2.2 Development Status Quo of China's Online Pharmacies
5.2.3 Problems Existing in the Development of Online Pharmacies and Causes
5.2.4 Development Strategy of China's Online Pharmacies
5.3 Future Development Countermeasures
5.3.1 Training Professional Talents
5.3.2 Building the Perfect Information System and Realizing the Information Sharing
5.3.3 Forming an Unified Entirety
5.3.4 Declining the Logistics Costs of the Cross-Regional Chain
5.3.5 Opening up the Rural Market
5.3.6 Improving the Brand Awareness and Strengthening the Propaganda of Public Opinion




Companies Mentioned

Sinopharm Holding Guoda Drugstores Co., Ltd.
Chongqing Tongjunge Pharmacy Chain Store Co., Ltd.
Guangdong Dashenlin Chain Drugstore Co., Ltd.
China Nepstar Chain Drugstore Co., Ltd.
Chongqing Peace Pharmacy Chain Co., Ltd.
Yunnan Hongxiang Yixintang Pharmaceutical Co., Ltd.
Hubei Tongjitang Pharmacy Co., Ltd.
Liaoning CDFY Pharmacy Chain Co., Ltd.

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

  • $ 10995
  • Industry report
  • September 2016
  • by Global Data

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024 Summary Attention deficit hyperactivity disorder (ADHD) is characterized by excessive levels ...

Global Pharmaceutical Contract Manufacturing Organization (CMO) Market

Global Pharmaceutical Contract Manufacturing Organization (CMO) Market

  • $ 7000
  • Industry report
  • August 2016
  • by Frost & Sullivan

Emerging Business Models Drive Transformation The key objective of this research is to provide in-depth knowledge of the major global pharmaceutical CMO market segments—active pharmaceutical ingredients ...

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation

  • $ 6995
  • Industry report
  • November 2016
  • by GBI Research

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation Summary Asthma is a chronic condition affecting ...


ref:plp2013

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.